

An uMbrella study of Biomarker-driven Targeted therapy In patients with platinum-resistant recurrence OvariaN cancer

Trial setting: Ovarian cancer/Recurrent/Heavily-treated

Study Design: Umbrella study

Study coordinator: Jung-Yun Lee

Senior Investigator: Jae Weon Kim, Byoung Gie Kim


Statistician: June Lim, Byung Ho Nam

Project manager: Ju Yeon Yi

Grant support: Severance Hospital Research Fund for Clinical Excellence

Drug supply: AstraZeneca

Why biomarker-driven Umbrella study in recurrent OC?



Target sequencing



Molecular tumor board meeting

Platinum-resistant Recurrent Ovarian Cancer

After 2nd line of chemotherapy

HRR gene panel

HRD+

HRD-

random

PD-L1 expression by IHC

PD-L1+

PD-L1-

Olaparib+
Cediranib

Olaparib+
Durvalumab

Durvalumab+
SOC

Durvalumab+
Tremelimumab+
SOC

Biomarker 1

Biomarker 2

Targeted agents

Number	Gene Symbol
1	BRCA1
2	BRCA2
3	ATM
4	BRIP1
5	PALB2
6	RAD51C
7	BARD1
8	CDK12
9	CHEK1
10	CHEK2
11	FANCL
12	PPP2R2A
13	RAD51B
14	RAD51D
15	RAD54L

Open: Not yet recruiting
Status: FPI expected in Nov 2018
Target: Approximately 70 pts
Notes: pre-screening started

Primary endpoint: ORR
O+C or O+D is assumed with 30%
D+SOC or D+T+SOC is assumed with 25%
O,olaparib; C,cediranib; D, durvalumab; T, tremelimumab;
SOC, standard of care